30959-67-2

Basic information

• Product Name: Cefradine
• CAS NO: 30959-67-2
• Molecular Weight: 349.411
• Mol File: 30959-67-2.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: Cefradine(CAS DataBase Reference)
• NIST Chemistry Reference: Cefradine(30959-67-2)
• EPA Substance Registry System: Cefradine(30959-67-2)

Safety Data

• Hazardous Substances Data: 30959-67-2(Hazardous Substances Data)

Upstream product

• 31461-05-9 (6R)-3-methyl-8-oxo-7t-(trimethylsilanyl-amino)-(6rH)-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid trimethylsilanyl ester 
• 57872-59-0 (R)-2-(tert-butoxycarbonylamino)-2-(cyclohexa-1,4-dienyl)acetic acid 
• 22252-43-3 3-deacetyloxy-7-aminocephalosporanic acid 
• 26774-88-9 (R)?2?(2,5?dihydrophenyl)glycine 
• 57872-62-5 N-tert-butyloxycarbonylcefradine 

Relevant articles and documents

Synthesis of cephalosporin-type antibiotics by coupling of their β-lactam nucleus and racemic amino acid side chains using a clathration-induced asymmetric transformation

The cephalosporin-type antibiotics Cephalexin, Cephradine and Cefadroxil have been prepared by coupling of their β-lactam nucleus and racemic amino acid side chain precursors. The initially obtained mixture of cephalosporin epimers is subjected to a clathration-induced asymmetric transformation which results in the epimerization of the epi-cephalosporin into the cephalosporin with the correct diastereomeric configuration.

Cefradine compound prepared by adopting high-flux medicine crystal form rapid screening technology and preparation thereof

The invention discloses a cefradine compound prepared by adopting a high-flux medicine crystal form rapid screening technology. The 'high-end medicine product refined crystallization technology development and industrialization project' won the second prize of the national scientific and technological process in 2015, and the high-flux medicine crystal form rapid screening technology belongs to one of the high-end medicine product refined crystallization technology. The cefradine compound is measured by adopting X-ray powder diffraction, and main characteristic peaks represented by a diffraction angle 2 theta in an atlas are 11.46+/-0.2 degrees, 18.47+/-0.2 degrees, 20.85+/-0.2 degrees, 23.21+/-0.2 degrees and 29.32+/-0.2 degrees. The compound is high in purity, low in impurity content and good in flowability and stability. Meanwhile, the invention discloses a preparation prepared by adopting cefradine, and the preparation is the cefradine for injection. The preparation is simple in preparation process, does not need any excipient, has the better solubility and stability and is smaller in side effect compared with an existing preparation.

MANUFACTURING METHOD AND APPARATUS OF ULTRAFINE PARTICLES HAVING UNIFORM PARTICLE SIZE DISTRIBUTION

The present invention relates to a novel technology for forming fine particles with a size of 0.02?3 microns from a solid that can be dissolved in a liquid solvent and is not decomposed by heat. The particle preparation technology according to the present invention may be applicable to the fields of food, cosmetics, biopolymer, polymer compositions, and pharmaceuticals.